Phase I study of a combination of S-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer

Oncology

Volumn 69, Issue 3, 2005, Pages 261-268

  Ueda, Yuji ^a   Yamagishi, Hisakazu ^a   Ichikawa, Daisuke ^a   Morii, Jun ^b   Koizumi, Kinya ^b   Kakihara, Naoki ^c   Shimotsuma, Masataka ^c   Takenaka, Atsushi ^c   Yamashita, Tetsuro ^d   Kurioka, Hideaki ^d   Nishiyama, Masahiko ^f   Morita, Satoshi ^e   Nakamura, Kanae ^e   Sakamoto, Junichi ^e  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^c KYOTO SECOND RED CROSS HOSPITAL   (Japan)

^d KYOTO FIRST RED CROSS HOSPITAL   (Japan)

^e KYOTO UNIVERSITY   (Japan)

^f HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Gastric cancer; Paclitaxel; Phase I study; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; EVALUATION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MALE; NAUSEA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; RASH; SIDE EFFECT; STOMACH CARCINOMA; STOMATITIS; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXONIC ACID; PACLITAXEL; PYRIDINES; STOMACH NEOPLASMS; TEGAFUR; TREATMENT OUTCOME;

EID: 26444432198     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088072     Document Type: Article

References (48)

1. Velde C, Peeters K: The gastric cancer treatment controversy. J Clin Oncol 2003;21:2234-2236.
2. Shimada Y: Clinical trials for advanced gastrointestinal cancers in Japan. Cancer Chemother Pharmacol 1998;42(suppl):S80-S84.
3. Ajani JA: Current status of therapy for advanced gastric carcinoma. Oncology (Huntingt) 1998;12(8 suppl 6):99-102.
4. Glimelius B, Hotfmann K, Haglund U, Nyren O, Sjoden PO: Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994;5:189-190.
5. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M: Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591.
6. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG 9205). J Clin Oncol 2003;21:54-59.
7. Sakamoto J: A new paradigm of chemotherapy for gastric cancer: speeding up, and more clinical trials to catch up. Gastric Cancer 2002;5:55-57.
8. Maehara Y: S-1 in gastric cancer: a comprehensive review. Gastric Cancer 2003;6(suppl 1):2-8.
9. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M: Development of a novel form of an oral fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulation. Anticancer Drugs 1996;7:548-557.
10. Diasio RB: Clinical implication of dihydropyrimidine dehydrogenase inhibition. Oncology 1999;13(suppl 3):17-21.
11. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyrimidine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996;56:2602-2606.
12. Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Shirasaka T: Pharmacokinetic study of S-1, a novel oral fluorouracil anti-tumor drug. Clin Cancer Res 1999;5:2000-2005.
13. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-1720.
14. Koizumi W, Kurihara M, Nakano S, Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58:191-197.
15. Rowinsky EK, Donehower RC: Paclitaxel (Taxol). N Engl J Med 1995;332:1004-1014.
16. Shiff PB, Horwits SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980;77:1561-1565.
17. Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K, Akazawa S, Kitajima M, Kanamaru R, Taguchi T: An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 1998;21:416-419.
18. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, Miyata Y, Taguchi T: Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitive reactions. Ann Oncol 2001;12:1133-1137.
19. Yamaguchi K, Tada M, Horikoshi N, Otani T, Takiuchi H, Saitoh S, Kanamaru R, Kasai Y, Koizumi W, Sakata Y, Taguchi T: Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer 2002;5:90-95.
20. Ringel I, Horwitz SB: Paclitaxel affects microtubule dynamics and apoptosis. Adv Oncol 1999;15:11-17.
21. Torres K, Horwitz SB: Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 1998;58:3620-3626.
22. Murad A, Petroianu A, Guimaraes RC, Aragao BC, Cabral LOM, Scalabrini-Neto AO: Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer. Am J Clin Oncol 1999;22:580-586.
23. Fujitani K, Takiuchi H, Narahara H, Tamura T, Satomi E, Hirao M, Tsujinaka T, Furukawa H, Taguchi T: Phase I study of S1 plus paclitaxel in patients with advanced gastric cancer (abstract 1437). Proc Am Soc Clin Oncol 2003;22:358.
24. Tamai H, Ueda Y, Itoi H, Ichikawa D, Shiozaki A, Itoh N, Iwamoto A, Shimizu T, Yamagishi H: A feasibility study of weekly paclitaxel and dihydropyrimidine-dehydrogenase-inhibitory oral fluoropyrimidines for recurrent gastric cancer. Proc 5th Int Gastric Cancer Congress, 2003, p 170.
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Glabbeke M, Oostrom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
26. Longnecker SM, Donehower RC, Cates AE, Chen TL, Brundrett RB, Grochow LB, Ettinger DS, Colvin M: High performance liquid chromatographic assay for Taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 1987;71:53-59.
27. Kearns CM, Gianni L, Egorin MJ: Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 1995;22(suppl 6):16-23.
28. Fennelly D, Aghaianian C, Shapiro F, O'Flaherty C, McKenzie M, O'Connor C, Tong W, Norton L, Spriggs D: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997;15:187-192.
29. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS: Recurrence following curative resection for gastric cancer. Br J Surg 2000;87:236-242.
30. Roth AD: Chemotherapy in gastric cancer: a never ending saga. Ann Oncol 2003;14:175-177.
31. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Matsumura Y, Gotoh M: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89:2207-2212.
32. Mori T, Fujiwara Y, Yano M, Tamura S, Yasuda T, Takiguchi S, Monden M: Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer. Gastric Cancer 2003;6(suppl 1):13-18.
33. Yamagata S, Nakata B, Hirakawa K: Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer. Oncol Rep 2004;12:973-978.
34. Huizing MT, Rosing H, Huinink TB, Sombroek G, Dewji R, Beijnen JH: Increased paclitaxel levels in patients with ovary cancer and ascetic fluid (abstract 374). Proc Am Soc Clin Oncol 1996;15:180.
35. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL, Rubin S, Curtin J, Barakat R, Phillips M, Hurowitz L, Almodorones L, Hoskins W: Phase 1 trial of intraperitoneal Taxol: a gynecological oncology group study. J Clin Oncol 1992;10:1485-1491.
36. Kobayashi O, Konishi K, Kanari M, Cho H, Yoshikawa T, Tsuburaya A, Sairenji M, Motohashi H: Unusual survival more than 2 years with peritoneal metastases of gastric cancer. Gastric Cancer 2002;5:47-50.
37. Sakurai Y, Yoshida I, Tonomura S, Sakai W, Nakamura Y, Imazu H, Matsubara T, Ochiai M: Weekly administration of paclitaxel attenuated rectal stenosis caused by multiple peritoneal recurrence 8 years after the resection of gastric carcinoma. Gastric Cancer 2002;6:243-249.
38. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Locatelli A, Bonadonna G, Egorin MJ: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995;13:180-190.
39. Rose WC: Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies. J Natl Cancer Inst Monogr 1993;15:47-54.
40. Chang AY, Boros L, Asbury R, Hui L, Rubins J: Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer. Semin Oncol 1997;24:S17-69-S17-71.
41. Kouroussis C, Kakolyris S, Mavroudis D, Androulakis N, Kalbakis K, Agelaki S, Sarra E, Souglakos J, Christodoulakis M, Samonis G, Georgoulias V: A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors. Am J Clin Oncol 2001;24:404-407.
42. Kano Y, Akutsu M, Tsunoda S, Ando J, Matsui J, Suzuki K, Ikeda T, Inoue Y, Adachi KI: Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer 1996;74:704-710.
43. Chollet P, Schoffski P, Weigang-Kohler K, Schellens JHM, Cure H, Pavlidis N, Grunward V, DeBoer R, Wanders J, Fumoleau P: Phase II trial of S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC early clinical study group (ECSG). Eur J Cancer 2003;39:1264-1270.
44. Yamada Y, Yasui H, Goto A, Arai T, Ura T, Hamaguchi T, Muro K, Shimada Y, Shirao K: Phase I study of irinotecan and S-1 combination chemotherapy in patients with metastatic gastric cancer. Int J Clin Oncol 2003;8:374-380.
45. Ajani JA, Van Cutsem E, Moiseyenko V, Tjulandin S, Fodor M, Majlis A, Boni C, Zuber E, Blattmann A: Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomized phase III trial (V325) (abstract 999). Proc Am Soc Clin Oncol 2003;22:249.
46. Ajani JA, Baker J, Pisters PWT, Ho L, Mansfield PF, Feig BW, Charnsangavej C: CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma - results of a phase II study. Cancer 2002;94:641-646.
47. Byrd-Leifer CA, Block EF, Takeda K, Akira S, Ding A: The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol 2001;31:2448-2457.
48. Myoung H, Hong SD, Kim YY, Hong SP, Kim MJ: Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma. Cancer Lett 2001;163:191-200.